Clinical

Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.

Even with MINT's mandatory steroid taper, inebilizumab still cut exacerbation and rescue therapy rates versus placebo, said Richard Nowak, MD, MS

Ann Marie Navar, MD, PhD, on enlicitide's 60% LDL reduction, less than 50% ApoB lowering, fasting dosing rules, and how it compares with inclisiran.

Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.

Led by the moderator, the panelists discussed how lecanemab and donanemab differ in trial efficacy, dosing schedule, and administration route, and how ARIA — while it can sound alarming to patients — is usually asymptomatic and stratifiable by a patient's APOE4 status, requiring the most intensive MRI monitoring in the first six months of treatment before rates drop off.

Culture conversion alone cannot capture what patients experience during MAC treatment, and new patient-reported outcome data argue for a more multidimensional definition of treatment success.

Early data on inhaled clofazimine suggest the drug can reach the lung at meaningful concentrations with far less systemic exposure than oral therapy, though efficacy evidence remains preliminary.

The panelists examined the full treatment continuum for Alzheimer's disease.

An independent review of BTK inhibitors in mantle cell lymphoma finds areas are of strength both second-generation therapies, as authors call for clinical trials to inform guidelines.

Yet H. Khor, MD, PhD, explains why a 20% emphysema threshold on CT imaging may better define combined PF and emphysema in fibrotic ILD.

Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.

Tozorakimab targets IL-33 upstream of TH2 pathways, cutting COPD exacerbations up to 34% in former smokers, Frank Sciurba, MD, explained.

Francesca Polverino, MD, PhD, says COPD exacerbation severity lacks a clear definition, complicating GOLD's escalation criteria.

Led by the moderator, the panelists discussed brexpiprazole's pivotal two-phase trial design and how its reduced intrinsic dopamine partial agonism and lower starting doses contributed to fewer akathisia events than aripiprazole, followed by cariprazine's D3-preferring mechanism and more favorable metabolic and sedation profile.

The panelists examined aripiprazole's pivotal trial design, which used an antidepressant lead-in phase followed by randomization to placebo or active drug among non-responders, with Thase detailing how dose-finding evolved toward lower 5 mg and 10 mg doses to minimize akathisia, the primary dose-limiting side effect, while preserving antidepressant benefit at doses lower than those used for antipsychotic indications.

A higher weight-adjusted waist index (WWI) was independently linked to greater all-cause and CVD mortality in CKD, partly via inflammation.

The Be Well trials narrowed eligibility to a specific surface antigen window, a design choice with real implications for which patients could benefit first. This episode reviews that rationale and its practice impact.

Repigmentation unfolds over months, not weeks, and Dr. Desai argues that managing expectations from the first visit matters as much as the medication itself. Dr. Lal adds that clinical-trial consistency rarely mirrors real-world adherence.

Without a head-to-head trial, comparing JAK inhibitors requires care. Dr. Rosmarin urges matching time points before drawing conclusions, while Jason explains how payers weigh incomplete data, member churn, and documentation when building coverage exceptions.

Bepirovirsen's antisense mechanism raises a genuinely unsettled question: how much of its effect comes from direct antiviral activity versus an unexpected immune response. This episode unpacks that debate.

Yet Khor discusses why a 20% CT emphysema threshold, not spirometry alone, best identifies CPFE and predicts outcomes in fibrotic ILD.

A national study found comorbidities may drive worse long-term survival among patients with MASH awaiting or undergoing liver transplant.

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status and eosinophil levels.

FDA approved zilganersen (ZANVASTRO), the first disease-modifying treatment for Alexander disease, based on pivotal trial data.

An all-oral, bedaquiline-containing regimen offers a potential salvage option for refractory MAC, reducing reliance on aminoglycoside therapy while requiring continued QT monitoring.